LiviWell raises US$3.3m for vaginal health device

LiviWell has raised US$3.3m seed funding to advance FDA clearance and ready the launch of Livi, a post-intercourse device for vaginal microbiome balance.

Livi is a medical-grade polyurethane foam device inserted with an applicator immediately after intercourse. It absorbs semen and other fluids in under 60 seconds, helping to maintain vaginal pH and support the microbiome. The vaginal microbiome is the community of helpful bacteria that helps keep acidity in check.

LiviWell submitted Livi to the FDA in June 2025 and expects a decision in the coming months. The company says that, once cleared, Livi will be positioned as the first authorised product of its kind for post-intercourse vaginal care. The device has been tested in clinical trials led by physicians in women’s pelvic health.

“We are deeply grateful to our investors for believing in our vision and mission,” said Dawn Halkuff, chief executive of LiviWell. “This funding represents more than capital—it’s a validation of our team’s dedication and the potential impact Livi can have on women’s sexual health and quality of life. With this support, we’re positioned to navigate the FDA clearance process and bring Livi to the women who need it most.”

The oversubscribed seed round totalled US$3.3m and was anchored by Atlantic Venture Studio, a subsidiary of Atlantic Health System. LiviWell is based in Mountain Lakes, New Jersey.